BR9907647A - Composições contendo composto orgânicos - Google Patents
Composições contendo composto orgânicosInfo
- Publication number
- BR9907647A BR9907647A BR9907647-0A BR9907647A BR9907647A BR 9907647 A BR9907647 A BR 9907647A BR 9907647 A BR9907647 A BR 9907647A BR 9907647 A BR9907647 A BR 9907647A
- Authority
- BR
- Brazil
- Prior art keywords
- organic compounds
- compositions containing
- containing organic
- epothilone
- infusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9802451.6A GB9802451D0 (en) | 1998-02-05 | 1998-02-05 | Organic compounds |
GBGB9813646.8A GB9813646D0 (en) | 1998-06-24 | 1998-06-24 | Organic compounds |
GB9802451.6 | 1998-06-24 | ||
GB9813646.8 | 1998-06-24 | ||
PCT/EP1999/000702 WO1999039694A2 (en) | 1998-02-05 | 1999-02-03 | Compositions containing organic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
BR9907647A true BR9907647A (pt) | 2000-11-14 |
BR9907647B1 BR9907647B1 (pt) | 2014-04-01 |
Family
ID=26313062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI9907647-0A BR9907647B1 (pt) | 1998-02-05 | 1999-02-03 | Formulação farmacêutica na forma de um concentrado para infusão, o qual deve ser diluído antes da administração, e solução para infusão |
Country Status (37)
Country | Link |
---|---|
US (5) | US20030203876A1 (pt) |
EP (1) | EP1052974B1 (pt) |
JP (2) | JP4644364B2 (pt) |
KR (3) | KR100669174B1 (pt) |
CN (2) | CN1623543A (pt) |
AR (1) | AR017979A1 (pt) |
AT (1) | ATE431733T1 (pt) |
AU (1) | AU753519B2 (pt) |
BE (1) | BE1012140A3 (pt) |
BR (1) | BR9907647B1 (pt) |
CA (1) | CA2320182C (pt) |
CL (1) | CL2003002786A1 (pt) |
CO (1) | CO4920246A1 (pt) |
CY (1) | CY1109311T1 (pt) |
CZ (1) | CZ303168B6 (pt) |
DE (1) | DE69940904D1 (pt) |
DK (1) | DK1052974T3 (pt) |
ES (1) | ES2324378T3 (pt) |
FR (1) | FR2774909B1 (pt) |
HK (1) | HK1033809A1 (pt) |
HU (1) | HUP0101564A3 (pt) |
ID (1) | ID26549A (pt) |
IL (2) | IL137550A0 (pt) |
IT (1) | IT1313549B1 (pt) |
MX (1) | MXPA00007681A (pt) |
MY (1) | MY125921A (pt) |
NO (2) | NO329376B1 (pt) |
NZ (1) | NZ506389A (pt) |
PE (1) | PE20000272A1 (pt) |
PL (1) | PL201329B1 (pt) |
PT (1) | PT1052974E (pt) |
RU (1) | RU2214246C2 (pt) |
SI (1) | SI1052974T1 (pt) |
SK (2) | SK287775B6 (pt) |
TR (1) | TR200002299T2 (pt) |
TW (1) | TW457095B (pt) |
WO (1) | WO1999039694A2 (pt) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
DE59610712D1 (de) | 1995-11-17 | 2003-10-16 | Biotechnolog Forschung Gmbh | Epothilonderivate, herstellung und verwendung |
CZ303422B6 (cs) | 1996-11-18 | 2012-09-05 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilon C, zpusob jeho výroby a jeho použití jako cytostatik a prostredku pro ochranu rostlin |
EP1386922B1 (en) | 1996-12-03 | 2012-04-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
GB9802451D0 (en) * | 1998-02-05 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6303342B1 (en) | 1998-11-20 | 2001-10-16 | Kason Biosciences, Inc. | Recombinant methods and materials for producing epothilones C and D |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
US6518421B1 (en) * | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
US6589968B2 (en) | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
AU2002245296B2 (en) * | 2001-01-25 | 2006-12-21 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
IL156580A0 (en) | 2001-01-25 | 2004-01-04 | Bristol Myers Squibb Co | A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog |
WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
ES2304240T3 (es) | 2001-01-25 | 2008-10-01 | Bristol-Myers Squibb Company | Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer. |
US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
BR0207487A (pt) | 2001-02-20 | 2004-08-10 | Brystol Myers Squibb Company | Método de tratamento de tumores em mamìferos e uso de compostos de epotilona |
BR0207316A (pt) | 2001-02-20 | 2004-02-10 | Bristol Myers Squibb Co | Derivados de epotilona para o tratamento de tumores refratários |
RU2321400C2 (ru) | 2001-03-14 | 2008-04-10 | Бристол-Маерс Сквибб Компани | Композиция аналога эпотилона в сочетании с химиотерапевтическими агентами для лечения рака |
KR100863089B1 (ko) * | 2001-03-19 | 2008-10-13 | 노파르티스 아게 | 지사제 및 에포틸론 또는 에포틸론 유도체를 포함하는혼합물 |
JP2004532888A (ja) | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体 |
AU2008203233B2 (en) * | 2001-07-19 | 2010-04-29 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
TWI315982B (en) * | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
CN1615136A (zh) | 2002-01-14 | 2005-05-11 | 诺瓦提斯公司 | 包含埃坡霉素和抗代谢物的组合 |
WO2003077903A1 (en) | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
PL372070A1 (en) * | 2002-06-10 | 2005-07-11 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
WO2003105828A1 (en) | 2002-06-14 | 2003-12-24 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DK1506203T3 (da) | 2002-08-23 | 2007-05-14 | Sloan Kettering Inst Cancer | Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf |
MXPA05003006A (es) | 2002-09-23 | 2005-06-22 | Squibb Bristol Myers Co | Metodos para la preparacion, aislamiento y purificacion de epotilona b y estructuras cristalinas de rayos x y de epotilona b. |
US7091193B2 (en) | 2002-10-09 | 2006-08-15 | Kosan Biosciences Incorporated | Therapeutic formulations |
SI1553938T1 (sl) * | 2002-10-15 | 2007-06-30 | Univ Louisiana State | Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma |
AU2003291337B2 (en) | 2002-11-07 | 2010-09-09 | Kosan Biosciences Incorporated | Trans-9,10-dehydroepothilone C and D, analogs thereof and methos of making the same |
KR20060122819A (ko) * | 2003-10-09 | 2006-11-30 | 코산 바이오사이언시즈, 인코포레이티드 | 치료학적 제형 |
US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
KR20060127946A (ko) * | 2004-01-29 | 2006-12-13 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 매크롤라이드계 화합물의 안정화 방법 |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
CN100409846C (zh) * | 2005-11-22 | 2008-08-13 | 菏泽睿鹰制药集团有限公司 | 一种埃坡霉素b脂质体制剂及应用 |
JP2010500387A (ja) | 2006-08-16 | 2010-01-07 | ノバルティス アクチエンゲゼルシャフト | 結晶形態のエポチロンbおよび医薬組成物における使用 |
EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
CN101642453B (zh) * | 2009-09-15 | 2011-03-16 | 湖南迪诺制药有限公司 | 一种含有埃坡霉素b的药物制剂 |
GB201505347D0 (en) * | 2015-03-27 | 2015-05-13 | Salupont Consulting Ltd | Sterilisation of s-nitrosothiols |
JP7271517B2 (ja) * | 2017-09-27 | 2023-05-11 | ノバルティス アーゲー | シポニモドを含む非経口製剤 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) * | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
IL27947A (en) * | 1967-05-09 | 1972-07-26 | Weitzman J | Method for the production of thermoplastic resin particles and of mixtures of such particles with additives |
JPS56115855A (en) * | 1980-02-19 | 1981-09-11 | Toyota Motor Corp | Method and apparatus for controlling ignition timing of engine |
US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
HU191101B (en) * | 1983-02-14 | 1987-01-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups |
IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
FR2647343B1 (fr) * | 1989-05-24 | 1994-05-06 | Rhone Poulenc Sante | Nouvelle forme pharmaceutique poreuse et sa preparation |
US5216011A (en) * | 1989-09-01 | 1993-06-01 | Bristol-Myers Squibb Co. | Stable solutions of mitomycin c |
DE4138042C2 (de) * | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
CA2086874E (en) * | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
JPH0753396A (ja) * | 1993-08-19 | 1995-02-28 | Ensuiko Sugar Refining Co Ltd | タキソールのサイクロデキストリン包接物,その製造法および用途 |
CA2092271C (en) * | 1993-03-09 | 2009-10-13 | Eddie Reed | Use of g-csf for treating taxol side-effects |
HU213200B (en) * | 1993-05-12 | 1997-03-28 | Chinoin Gyogyszer Es Vegyeszet | The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production |
US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
FR2718963B1 (fr) * | 1994-04-25 | 1996-05-24 | Rhone Poulenc Rorer Sa | Nouvelle composition pharmaceutique à base de taxoïdes. |
US5616330A (en) * | 1994-07-19 | 1997-04-01 | Hemagen/Pfc | Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same |
HUT73844A (en) * | 1994-11-11 | 1996-09-30 | Chinoin Gyogyszer Es Vegyeszet | New taxol complexes and pharmaceutical compositions containing them |
JP3934705B2 (ja) * | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
DE59610712D1 (de) * | 1995-11-17 | 2003-10-16 | Biotechnolog Forschung Gmbh | Epothilonderivate, herstellung und verwendung |
CN101028259A (zh) * | 1996-03-12 | 2007-09-05 | Pg-Txl有限公司 | 水溶性紫杉醇产品 |
US5877205A (en) * | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
EP1386922B1 (en) * | 1996-12-03 | 2012-04-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
-
1999
- 1999-02-03 KR KR1020007008399A patent/KR100669174B1/ko not_active IP Right Cessation
- 1999-02-03 MX MXPA00007681A patent/MXPA00007681A/es active IP Right Grant
- 1999-02-03 AR ARP990100446A patent/AR017979A1/es not_active Application Discontinuation
- 1999-02-03 RU RU2000123171/14A patent/RU2214246C2/ru not_active IP Right Cessation
- 1999-02-03 KR KR1020057022710A patent/KR20060002022A/ko not_active Application Discontinuation
- 1999-02-03 AT AT99907491T patent/ATE431733T1/de active
- 1999-02-03 SI SI9931034T patent/SI1052974T1/sl unknown
- 1999-02-03 CZ CZ20002834A patent/CZ303168B6/cs not_active IP Right Cessation
- 1999-02-03 ES ES99907491T patent/ES2324378T3/es not_active Expired - Lifetime
- 1999-02-03 PL PL342629A patent/PL201329B1/pl unknown
- 1999-02-03 JP JP2000530194A patent/JP4644364B2/ja not_active Expired - Fee Related
- 1999-02-03 DE DE69940904T patent/DE69940904D1/de not_active Expired - Lifetime
- 1999-02-03 PT PT99907491T patent/PT1052974E/pt unknown
- 1999-02-03 KR KR1020087003239A patent/KR20080016756A/ko not_active Application Discontinuation
- 1999-02-03 MY MYPI99000384A patent/MY125921A/en unknown
- 1999-02-03 SK SK1170-2000A patent/SK287775B6/sk not_active IP Right Cessation
- 1999-02-03 ID IDW20001472A patent/ID26549A/id unknown
- 1999-02-03 HU HU0101564A patent/HUP0101564A3/hu unknown
- 1999-02-03 DK DK99907491T patent/DK1052974T3/da active
- 1999-02-03 BR BRPI9907647-0A patent/BR9907647B1/pt not_active IP Right Cessation
- 1999-02-03 EP EP99907491A patent/EP1052974B1/en not_active Revoked
- 1999-02-03 TR TR2000/02299T patent/TR200002299T2/xx unknown
- 1999-02-03 AU AU27226/99A patent/AU753519B2/en not_active Ceased
- 1999-02-03 CN CNA2004100058263A patent/CN1623543A/zh active Pending
- 1999-02-03 CA CA002320182A patent/CA2320182C/en not_active Expired - Fee Related
- 1999-02-03 SK SK5020-2009A patent/SK287487B6/sk not_active IP Right Cessation
- 1999-02-03 IL IL13755099A patent/IL137550A0/xx unknown
- 1999-02-03 NZ NZ506389A patent/NZ506389A/en not_active IP Right Cessation
- 1999-02-03 TW TW088101639A patent/TW457095B/zh not_active IP Right Cessation
- 1999-02-03 CN CNB998036722A patent/CN100396276C/zh not_active Expired - Fee Related
- 1999-02-03 WO PCT/EP1999/000702 patent/WO1999039694A2/en active IP Right Grant
- 1999-02-04 IT IT1999MI000208A patent/IT1313549B1/it active
- 1999-02-04 BE BE9900077A patent/BE1012140A3/fr active
- 1999-02-04 CO CO99006429D patent/CO4920246A1/es unknown
- 1999-02-04 PE PE1999000092A patent/PE20000272A1/es not_active Application Discontinuation
- 1999-02-05 FR FR9901356A patent/FR2774909B1/fr not_active Expired - Fee Related
-
2000
- 2000-07-27 IL IL137550A patent/IL137550A/en not_active IP Right Cessation
- 2000-08-03 NO NO20003930A patent/NO329376B1/no not_active IP Right Cessation
-
2001
- 2001-05-22 HK HK01103518.6A patent/HK1033809A1/xx not_active IP Right Cessation
-
2003
- 2003-04-09 US US10/410,376 patent/US20030203876A1/en not_active Abandoned
- 2003-12-30 CL CL200302786A patent/CL2003002786A1/es unknown
-
2006
- 2006-01-31 US US11/343,827 patent/US20060127423A1/en not_active Abandoned
- 2006-11-13 US US11/598,506 patent/US20070060627A1/en not_active Abandoned
-
2008
- 2008-05-20 US US12/123,639 patent/US20080221065A1/en not_active Abandoned
-
2009
- 2009-08-12 CY CY20091100866T patent/CY1109311T1/el unknown
- 2009-12-08 JP JP2009278624A patent/JP2010090147A/ja active Pending
-
2010
- 2010-03-04 NO NO20100302A patent/NO20100302L/no unknown
-
2011
- 2011-02-04 US US13/020,907 patent/US20110124691A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9907647A (pt) | Composições contendo composto orgânicos | |
ATE270544T1 (de) | Halbfeste arzneizubereitung enthaltend isotretinoin | |
BR0107147A (pt) | Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações | |
BR0009564A (pt) | Utilização de inibidores da cyp2d6 em terapias de combinação | |
SV1999000049A (es) | Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
IT1309427B1 (it) | Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso | |
BR9810495A (pt) | Composição farmacêutica | |
BRPI0414565A (pt) | composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato | |
BR9916575A (pt) | Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa | |
BR9811458A (pt) | "sistema solvente para penetração melhorada de compostos farmacêuticos" | |
ES2124477T3 (es) | Uso de un fosfato de ascorbilo y tocoferilo para la preparacion de un medicamento para el tratamiento de la pancreatitis. | |
PA8496701A1 (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2] oct- 3 - ilamina y sus composiciones farmaceuticas | |
BR0011845A (pt) | Complexo farmacêutico | |
IT1298442B1 (it) | Composizioni orali a basso dosaggio di proteine citotossiche | |
PA8496001A1 (es) | Polimorfos de un citrato de azobiciclo [2.2.2] oct-3-ilamina cristalino y sus composiciones farmaceuticas | |
BR9810387A (pt) | (s) 3, 4, 5-trimetoxibenzoato de 2-metilamino-2-fenil-n-butila, e sua aplicação para o tratamento de dor crÈnica | |
DK1100463T3 (da) | Injicerbare formuleringer indeholdende ramoplanin | |
BR0000011A (pt) | Composições injetáveis de alatrofloxacina pré-mistruadas | |
BR0009113A (pt) | Composição farmacêutica à base de compostospoliaromáticos | |
BRPI0412681A (pt) | composição farmacêutica para a administração por via nasal de piribedil | |
DE60023307D1 (de) | Phenanthrolin-7-onderivate und ihre therapeutische verwendung | |
DE69901721D1 (de) | Pharmazeutische zusammensetzungen basierend auf alpha-cyclodextrin zur oralen verabreichung von lh-rh analogen | |
ECSP992852A (es) | Compuestos organicos | |
GB9802451D0 (en) | Organic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: APRESENTAR NA INTEGRA COPIA DAS DUAS PRIORIDADE REIVINDICADAS NO PEDIDO |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/04/2014, OBSERVADAS AS CONDICOES LEGAIS. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2363 DE 19-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |